Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hospitalized Patients
100%
Surveillance Studies
100%
Antifungal Therapy
100%
C.albicans
100%
Candidemia
100%
C.glabrata
100%
Prospective Surveillance
100%
Epidemiological Risk
100%
Scotland
40%
Candida
40%
Risk Factors
20%
National Health Service
20%
Mechanical Ventilation
20%
MALDI-TOF
20%
Intensive Care
20%
Number of Days
20%
Poor Clinical Outcomes
20%
Antifungal Susceptibility
20%
Candida Albicans (C. albicans)
20%
Broth Microdilution
20%
Catheter
20%
Predisposing Factors
20%
Echinocandins
20%
Candida Bloodstream Infection
20%
Epidemiology
20%
Chromogenic Agar
20%
Survival Risk Factors
20%
Candida Isolates
20%
EUCAST Breakpoints
20%
Non-albicans
20%
TOF Method
20%
Blood Culture
20%
Albicans
20%
CLSI Breakpoints
20%
Fluconazole Resistance
20%
MIC Test
20%
Line Removal
20%
One Percent
20%
Associated Risk Factors
20%
European Committee on Antimicrobial Susceptibility Testing (EUCAST)
20%
Parapsilosis
20%
Fluconazole
20%
Patient Survival
20%
Anidulafungin
20%
Total Parenteral nutrition
20%
Medicine and Dentistry
Antifungal Therapy
100%
Cohort Effect
100%
Candidemia
100%
Infection
66%
Fluconazole
66%
Intensive Care
33%
National Health Service
33%
Artificial Respiration
33%
Bloodstream Infection
33%
Total Parenteral Nutrition
33%
Anidulafungin
33%
Disease Predisposition
33%
Agar
33%
Antifungal Susceptibility
33%
Blood Culture
33%
Echinocandin
33%
Matrix-Assisted Laser Desorption-Ionization
33%
Pharmacology, Toxicology and Pharmaceutical Science
Candida Albicans
100%
Candidemia
100%
Candida
66%
Infection
33%
Fluconazole
33%
Agar
16%
Bloodstream Infection
16%
Anidulafungin
16%
Disease Predisposition
16%
Echinocandin
16%
Immunology and Microbiology
Candida Albicans
100%
Candida
66%
Matrix-Assisted Laser Desorption-Ionization
16%
Agar
16%
Antifungal Susceptibility
16%
Broth Dilution
16%
Minimum Inhibitory Concentration
16%